Arrivent Biopharma Inc (AVBP)

05:26 AM

Where are the Opportunities in (AVBP) - Stock Traders Daily

05:26 AM

Feb 19, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - MarketBeat

Feb 19, 2025

Feb 16, 2025

Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Feb 16, 2025

Feb 16, 2025

Mirae Asset Global Investments Co. Ltd. Purchases Shares of 1,123 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Armenian Reporter

Feb 16, 2025

Feb 11, 2025

How To Trade (AVBP) - Stock Traders Daily

Feb 11, 2025

Feb 06, 2025

Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Expands By 13.1% - MarketBeat

Feb 06, 2025

Feb 05, 2025

Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - News & Insights

Feb 05, 2025

Feb 04, 2025

Asia’s NewCo Model, FDA tipping point, Vertex’s pain drug: a BioCentury podcast - BioCentury

Feb 04, 2025

Jan 31, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World

Jan 31, 2025

Jan 30, 2025

(AVBP) Trading Signals - Stock Traders Daily

Jan 30, 2025

Jan 28, 2025

Abbvie seeks molecular glue degraders from Neomorph - BioCentury

Jan 28, 2025

Jan 27, 2025

ArriVent in Newtown Square Sees Big Potential in New Cancer Drug - DELCO.Today

Jan 27, 2025

Jan 27, 2025

ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN

Jan 27, 2025

Jan 27, 2025

Lepu Biopharma’s $1.6 Billion ADC Licensing Agreement with ArriVent Biopharma - Global Legal Chronicle

Jan 27, 2025

Jan 25, 2025

Equities Analysts Set Expectations for AVBP Q1 Earnings - Defense World

Jan 25, 2025

Jan 24, 2025

HC Wainwright Issues Positive Estimate for AVBP Earnings - MarketBeat

Jan 24, 2025

Jan 23, 2025

More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal - BioWorld Online

Jan 23, 2025

Jan 23, 2025

ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright - Yahoo Finance

Jan 23, 2025

Jan 22, 2025

ArriVent Biopharma enters license agreement with Lepu Biopharma - MSN

Jan 22, 2025

Jan 22, 2025

Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim - MedCity News

Jan 22, 2025

Jan 22, 2025

Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive

Jan 22, 2025

Jan 22, 2025

ArriVent inks ADC licensing deal with Lepu Biopharma - The Pharma Letter

Jan 22, 2025

Jan 22, 2025

ArriVent bets big on experimental cancer drug with potential $1B licensing deal - The Business Journals

Jan 22, 2025

Jan 22, 2025

Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers - BioWorld Online

Jan 22, 2025

Jan 22, 2025

ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu - BioSpace

Jan 22, 2025

Jan 22, 2025

ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Jan 22, 2025

Jan 22, 2025

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - The Manila Times

Jan 22, 2025

Jan 21, 2025

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the - Digital More

Jan 21, 2025

Jan 21, 2025

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers - The Manila Times

Jan 21, 2025

Jan 21, 2025

Lepu Biopharma Co., Ltd. Enters into an Exclusive Licensing Agreement with Arrivent Biopharma, Inc - Marketscreener.com

Jan 21, 2025

Jan 21, 2025

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma - WICZ

Jan 21, 2025

Jan 21, 2025

Lepu Biopharma Grants Exclusive License for Novel ADC MRG007 to ArriVent - TipRanks

Jan 21, 2025

Jan 21, 2025

ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal - StockTitan

Jan 21, 2025

Jan 20, 2025

(AVBP) Investment Analysis - Stock Traders Daily

Jan 20, 2025

Jan 19, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.1% in December - MarketBeat

Jan 19, 2025

Jan 18, 2025

Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MyChesCo

Jan 18, 2025

Jan 17, 2025

ArriVent BioPharma (NASDAQ:AVBP) Shares Gap DownWhat's Next? - MarketBeat

Jan 17, 2025

Jan 16, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 16, 2025

Jan 15, 2025

Barclays PLC Has $976,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Jan 15, 2025

Jan 14, 2025

Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online

Jan 14, 2025

Jan 12, 2025

Jane Street Group LLC Has $250,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Jan 12, 2025

Jan 11, 2025

We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Simply Wall St

Jan 11, 2025

Jan 06, 2025

ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5%Should You Sell? - MarketBeat

Jan 06, 2025

Dec 31, 2024

Geode Capital Management LLC Increases Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Dec 31, 2024

Dec 31, 2024

Barclays PLC Increases Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Dec 31, 2024

Dec 31, 2024

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock Position Increased by Geode Capital Management LLC - MarketBeat

Dec 31, 2024

Dec 31, 2024

Barclays PLC Buys 38,132 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat

Dec 31, 2024

Dec 30, 2024

(AVBP) Proactive Strategies - Stock Traders Daily

Dec 30, 2024

Dec 26, 2024

State Street Corp Acquires 323,186 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat

Dec 26, 2024

Dec 26, 2024

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stake Lifted by State Street Corp - Defense World

Dec 26, 2024